A phase IIa, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutatio

Phase 2

Completed

• Conditions: Cystic Fibrosis; 10083624

• Registration Number: NL-OMON43806
• Lead Sponsor: Galapagos NV

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 4

Inclusion Criteria

1.Male or female subjects >= 18 years of age, on the day of signing the
Informed Consent Form (ICF), with a confirmed diagnosis of cystic
fibrosis:
a. Clinical diagnosis of cystic fibrosis with signs/symptoms involving at
least two organ systems, and
b. Medical history of elevated sweat chloride >=60 mmol/L by
quantitative pilocarpine iontophoresis (documented in the subject's
medical record) or 2 disease causing CFTR mutations (documented in the
subject's medical record).
2.Gating S1251N CFTR mutation on at least one allele in the CFTR gene
(documented in the subject's medical record or CF registry); any known
or unknown mutation allowed on the 2nd allele. Subject inclusion can be
performed, provided that genotype information is available in source
data.
3.Subject must meet one of the following:
a. Subjects currently receiving treatment with ivacaftor must be on a
stable regimen for at least 2 weeks prior to screening
Or
b. Subjects not on a treatment regimen with ivacaftor for at least 2weeks prior to screening
4.Weight >= 40.0 kg.
5.Subjects on stable concomitant treatment regimen for at least 4 weeks
prior to baseline (excluding ivacaftor).
6.Pre- or post-bronchodilator FEV1 >= 40% of predicted normal for age,
gender, height at screening.
7.Female subjects must have a negative blood pregnancy test.
Determination of serum follicle-stimulating hormone (FSH) will be done
for any suspected postmenopausal female with at least 12 months of
continuous spontaneous amenorrhea, with FSH levels > 40 IU/mL being
confirmative for menopause. For hysterectomy and tubal ligation,
documented confirmation will be requested.
8.Subjects will have to use highly effective contraceptive methods prior
to the first dose of the study drug, during the study, and for at least 12
weeks after the last dose of the study drug.
a. If the subject is a sexually active woman of childbearing potential, she
and her male partner are required to simultaneously use 2 effective
contraceptive methods as listed in the protocol. Hormonal contraceptives
will not be considered as an effective method; however, female subjects
are not required to discontinue hormonal contraceptives. Female
subjects who use contraception must have done so for at least 14 days
prior to the first dose of the study drug.
b. Non-vasectomized sexually active male subjects with female partners
of childbearing potential must be willing to use a condom in addition to
having their female partner use another form of contraception as listed
in the protocol.

Exclusion Criteria

1.History of sensitivity to any component of the study drug, or a history
of drug or other allergy that, in the investigator's opinion,
contraindicates the subject's participation in the study.
2.On an ivacaftor-containing treatment regimen and unable or unwilling
to discontinue ivacaftor for the washout and treatment periods of the
study.
3.Concomitant use of antifungal drugs (e.g. itraconazole, ketoconazole,
voriconazole, posaconazole) within 4 weeks of baseline.
4.A history of a clinically meaningful unstable or uncontrolled chronic
disease including underlying cystic fibrosis that makes the subject
unsuitable for inclusion in the study in the opinion of the investigator.
5.Liver cirrhosis and portal hypertension.
6.History of malignancy within the past 5 years (except for carcinoma in
situ of the uterine cervix and basal cell carcinoma of the skin that has
been treated with no evidence of recurrence).
7.Any significant change in the medical regimen (including dose and
frequency) for pulmonary health within 4 weeks of baseline, including:
antibiotics; corticosteroids (as defined in the protocol); inhaled
bronchodilators, hypertonic saline, mannitol or dornase alfa; ibuprofen
and airway clearance techniques. Individuals taking inhaled antibiotics
for suppression of chronic airways infection must be on a stable regimen
for at least 8 weeks prior to baseline and willing to continue the same
antibiotic through Day 29.
8.Unstable pulmonary status or respiratory tract infection (including
pulmonary exacerbation), based on the investigator's opinion, or
changes in therapy for pulmonary disease within 4 weeks of baseline as
defined in the protocol.
9.History of lung volume reduction surgery or lung transplant.
10.Use of continuous (24 hours per day) supplemental oxygen therapy.
11.Clinically significant abnormalities detected on electrocardiogram
(ECG) regarding either rhythm or conduction (e.g., QTcF >= 450 ms, or aknown long QT syndrome). A first degree heart block will not be
considered as a significant abnormality.
12.Use of medication known to prolong the QT interval (including herbal
and naturopathic therapy).
13.History of solid organ or haematological transplantation or currently
on a transplantation waiting list.
14.Abnormal liver function defined as aspartate aminotransferase (AST),
alanine aminotransferase (ALT), GGT > 3 x upper limit of the normal
range or bilirubin > 2 x upper limit of the normal range.
15.Abnormal renal function defined as creatinine clearance < 50mL/min
using the Cockroft-Gault equation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety and tolerability will be assessed through:<br /><br>•Adverse events (AEs)<br /><br>•Physical examinations<br /><br>•Vital signs<br /><br>•12-lead ECG<br /><br>•Oxygen saturation<br /><br>•Safety laboratory assessments</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Efficacy will be assessed through:<br /><br>•sweat chloride concentration testing<br /><br>•measuring pulmonary function</p><br>